Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Anidulafungin Articles

Inconclusive Ph III results for Pfizer’s Vfend and Eraxis combo in fungal infections

3 October 2011

Pfizer licenses MultiStem IBD drug from Athersys for as much as $111 million; sells Vicuron subsid

22 December 2009

Health Canada approves Pfizer's Eraxis

3 December 2007

US FDA approves quit smoking Rx drug Chantix, Pfizer forecasts $1.2B sales by 2010

22 May 2006

US FDA OKs Pfizer's Eraxis for first launch

27 February 2006

Pfizer to buy biotech Vicuron in $1.9B deal to gain anti-infective drugs

27 June 2005

Vicuron amends its IND for anidulafungin

6 June 2005

Vicuron and Pfizer extend collaboration

18 April 2005

Vicuron's anti-fungal "superior" to Pfizer's

14 February 2005

Vicuron to reduce costs due to anidulaflungin delay

28 June 2004

Vicuron's antifungal faces delay in USA

31 May 2004

FDA requires more time to review Vicuron's antifungal agent

2 February 2004

Vicuron antifungal promising in Phase II

19 May 2003

Vicuron files NDA for anidulafungin in USA

5 May 2003

Positive PH II results for Versicor's anidulafungin

24 March 2003

Losses double at Versicor

25 February 2002

Versicor starts pivotal trials of antifungal

14 January 2002

Showing 1-17 of 17 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Italy's pharma market slump set to continue, warns GlobalData
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Italy's pharma market slump set to continue, warns GlobalData

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS